In addition, simplified dosing regimens and reduced administration constraints are expected to improve treatment adherence and expand adoption across a broader patient population, strengthening the competitive position of oral therapies within the metabolic disease treatment landscape
Following an FDA announcement on its deeper look into peptide restrictions, Christopher Shade, PhD, joined to provide insights on their functions for metabolic health and more
Find Your Club Explore The Club Collection With 17 exceptional country clubs across the UK, membership to The Club Company gives you more, with access to golf, health, spa and stay across the collection.
Additionally, Novo Nordisk will present mid-stage Phase 2 results for zenagamtide, an investigational peptide therapy targeting metabolic disorders
doi: 10.3389/fimmu.2014.00491 3 BenvenutiF.HuguesS.WalmsleyM.RufS.FetlerL.PopoffM.et al
Follow a Holistic Approach : Combine injections with proper nutrition, exercise, sleep, and stress management